The emerging role of nontraditional ubiquitination in oncogenic pathways

Journal of Biological Chemistry

Volumn 292, Issue 9, 2017, Pages 3543-3551

  Dwane, Lisa ^a   Gallagher, William M ^b   Chonghaile, Tríona Ní ^a   O'Connor, Darran P ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

DATA MINING;

CELLULAR HOMEOSTASIS; KEY REGULATORS; NON-TRADITIONAL; ONCOGENIC PATHWAYS; PROTEIN TURNOVERS; PROTEOLYTIC FUNCTIONS; SIGNALING ENTITIES; TARGET PROTEINS;

PROTEINS;

BRCA1 PROTEIN; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; AKT1 PROTEIN, HUMAN; LYSINE; UBIQUITIN;

CANCER GROWTH; ENZYME INHIBITION; FANCONI ANEMIA; HISTONE MODIFICATION; HUMAN; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CARCINOGENESIS; CATALYSIS; CHEMISTRY; GENE EXPRESSION REGULATION; HOMEOSTASIS; METABOLISM; NEOPLASM; ONCOGENE; PROTEIN PROCESSING; PROTEIN TRANSPORT;

ANIMALS; CARCINOGENESIS; CATALYSIS; FANCONI ANEMIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEOSTASIS; HUMANS; LYSINE; NEOPLASMS; NF-KAPPA B; ONCOGENES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; UBIQUITIN; UBIQUITINATION;

EID: 85014629729     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.R116.755694     Document Type: Review

References (91)

1. Wang, Y. C., Peterson, S. E., and Loring, J. F. (2014) Protein post-translational modifications and regulation of pluripotency in human stem cells. Cell Res. 24, 143-160
2. Hershko, A., and Ciechanover, A. (1998) The ubiquitin system. Annu. Rev. Biochem. 67, 425-479
3. Haas, A. L., and Siepmann, T. J. (1997) Pathways of ubiquitin conjugation. FASEB J. 11, 1257-1268
4. Ciechanover, A., Orian, A., and Schwartz, A. L. (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22, 442-451
5. Ciechanover, A., and Ben-Saadon, R. (2004) N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol. 14, 103-106
6. Kravtsova-Ivantsiv, Y., and Ciechanover, A. (2012) Non-canonical ubiquitin-based signals for proteasomal degradation. J. Cell Sci. 125, 539-548
7. Cadwell, K., and Coscoy, L. (2005) Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 309, 127-130
8. Suryadinata, R., Roesley, S. N., Yang, G., and Sarc?evic, B. (2014) Mechanisms of generating polyubiquitin chains of different topology. Cells 3, 674-689
9. Pickart, C. M. (2001) Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533
10. Pickart, C. M., and Eddins, M. J. (2004) Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695, 55-72
11. Haglund, K., Di Fiore, P. P., and Dikic, I. (2003) Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem. Sci. 28, 598-603
12. Cole, A. J., Clifton-Bligh, R., and Marsh, D. J. (2015) Histone H2B monoubiquitination: roles to play in human malignancy. Endocr.-Relat. Cancer 22, T19-T33
13. Messick, T. E., and Greenberg, R. A. (2009) The ubiquitin landscape at DNA double-strand breaks. J. Cell Biol. 187, 319-326
14. Erpapazoglou, Z., Walker, O., and Haguenauer-Tsapis, R. (2014) Versatile roles of K63-linked ubiquitin chains in trafficking. Cells 3, 1027-1088
15. Vallabhapurapu, S., and Karin, M. (2009) Regulation and function of NF-B transcription factors in the immune system. Annu. Rev. Immunol. 27, 693-733
16. Wang, G., Gao, Y., Li, L., Jin, G., Cai, Z., Chao, J. I., and Lin, H. K. (2012) K63-linked ubiquitination in kinase activation and cancer. Front. Oncol. 2, 5
17. Spence, J., Sadis, S., Haas, A. L., and Finley, D. (1995) A ubiquitin mutant with specific defects in DNA repair and multiubiquitination. Mol. Cell. Biol. 15, 1265-1273
18. Varadan, R., Walker, O., Pickart, C., and Fushman, D. (2002) Structural properties of polyubiquitin chains in solution. J. Mol. Biol. 324, 637-647
19. Varadan, R., Assfalg, M., Haririnia, A., Raasi, S., Pickart, C., and Fushman, D. (2004) Solution conformation of Lys63-linked di-ubiquitin chain provides clues to functional diversity of polyubiquitin signaling. J. Biol. Chem. 279, 7055-7063
20. Wu-Baer, F., Lagrazon, K., Yuan, W., and Baer, R. (2003) The BRCA1/ BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. J. Biol. Chem. 278, 34743-34746
21. Christensen, D. E., Brzovic, P. S., and Klevit, R. E. (2007) E2-BRCA1 RING interactions dictate synthesis of mono-or specific polyubiquitin chain linkages. Nat. Struct. Mol. Biol. 14, 941-948
22. Moreau, P., Richardson, P. G., Cavo, M., Orlowski, R. Z., San Miguel, J. F., Palumbo, A., and Harousseau, J. L. (2012) Proteasome inhibitors in multiple myeloma: 10 years later. Blood 120, 947-959
23. Bold, R. (2004) "Development of the proteasome inhibitor Velcade (Bortezomib)" by Julian Adams, Ph. D., and Michael Kauffman, M. D., Ph. D. Cancer Invest. 22, 328-329
24. Pellom, S. T., Jr., and Shanker, A. (2012) Development of proteasome inhibitors as therapeutic drugs. J. Clin. Cell. Immunol. S5, 5
25. Fostier, K., De Becker, A., and Schots, R. (2012) Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Onco Targets Ther. 5, 237-244
26. Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., Stoppa, A. M., Simpson, D. R., Gimsing, P., Palumbo, A., Garderet, L., et al. (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for multiple myeloma. N. Engl. J. Med. 374, 1621-1634
27. Chervona, Y., and Costa, M. (2012) Histone modifications and cancer: biomarkers of prognosis? Am. J. Cancer Res. 2, 589-597
28. Prenzel, T., Begus-Nahrmann, Y., Kramer, F., Hennion, M., Hsu, C., Gorsler, T., Hintermair, C., Eick, D., Kremmer, E., Simons, M., Beissbarth, T., and Johnsen, S. A. (2011) Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res. 71, 5739-5753
29. Fan, M., Nakshatri, H., and Nephew, K. P. (2004) Inhibiting proteasomal proteolysis sustains estrogen receptor- activation. Mol. Endocrinol. 18, 2603-2615
30. Oosterkamp, H. M., Hijmans, E. M., Brummelkamp, T. R., Canisius, S., Wessels, L. F., Zwart, W., and Bernards, R. (2014) USP9X downregulation renders breast cancer cells resistant to tamoxifen. Cancer Res. 74, 3810-3820
31. Cao, J., and Yan, Q. (2012) Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front. Oncol. 2, 26
32. Wu, Y., Chen, P., Jing, Y., Wang, C., Men, Y. L., Zhan, W., Wang, Q., Gan, Z., Huang, J., Xie, K., Mi, J., Yu, C., Yu, X., Chen, P. C., Chang, J. F., et al. (2015) Microarray analysis reveals potential biological functions of histone H2B monoubiquitination. PLoS One 10, e0133444
33. Wang, Z., Zhu, L., Guo, T., Wang, Y., and Yang, J. (2015) Decreased H2B monoubiquitination and overexpression of ubiquitin-specific protease enzyme 22 in malignant colon carcinoma. Hum. Pathol. 46, 1006-1014
34. Hahn, M. A., Dickson, K. A., Jackson, S., Clarkson, A., Gill, A. J., and Marsh, D. J. (2012) The tumor suppressor CDC73 interacts with the ring finger proteins RNF20 and RNF40 and is required for the maintenance of histone 2B monoubiquitination. Hum. Mol. Genet. 21, 559-568
35. Tarcic, O., Pateras, I. S., Cooks, T., Shema, E., Kanterman, J., Ashkenazi, H., Boocholez, H., Hubert, A., Rotkopf, R., Baniyash, M., Pikarsky, E., Gorgoulis, V. G., and Oren, M. (2016) RNF20 links histone H2B ubiquitylation with inflammation and inflammation-associated cancer. Cell Rep. 14, 1462-1476
36. Tang, B., Tang, F., Li, B., Yuan, S., Xu, Q., Tomlinson, S., Jin, J., Hu, W., and He, S. (2015) High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget 6, 12654-12667
37. Ding, F., Bao, C., Tian, Y., Xiao, H., Wang, M., Xie, X., Hu, F., and Mei, J. (2014) USP22 promotes NSCLC tumorigenesis viaMDMXup-regulation and subsequent p53 inhibition. Int. J. Mol. Sci. 16, 307-320
38. D'Arcy, P., Wang, X., and Linder, S. (2015) Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol. Ther. 147, 32-54
39. Mathew, C. G. (2006) Fanconi anaemia genes and susceptibility to cancer. Oncogene 25, 5875-5884
40. Jo, U., and Kim, H. (2015) Exploiting the Fanconi anemia pathway for targeted anti-cancer therapy. Mol. Cells 38, 669-676
41. Renaudin, X., Koch Lerner, L., Menck, C. F., and Rosselli, F. (2016) The ubiquitin family meets the Fanconi anemia proteins. Mutat. Res. Rev. Mutat. Res. 769, 36-46
42. Gregory, R. C., Taniguchi, T., and D'Andrea, A. D. (2003) Regulation of the Fanconi anemia pathway by monoubiquitination. Semin. Cancer Biol. 13, 77-82
43. Rickman, K. A., Lach, F. P., Abhyankar, A., Donovan, F. X., Sanborn, E. M., Kennedy, J. A., Sougnez, C., Gabriel, S. B., Elemento, O., Chandrasekharappa, S. C., Schindler, D., Auerbach, A. D., and Smogorzewska, A. (2015) Deficiency of UBE2T, the E2 ubiquitin ligase necessary for FANCD2 and FANCI ubiquitination, causes FA-T Subtype of Fanconi anemia. Cell Rep. 12, 35-41
44. Suresh, B., Kumar, A. M., Jeong, H. S., Cho, Y. H., Ramakrishna, S., and Kim, K. S. (2015) Regulation of Fanconi anemia protein FANCD2 monoubiquitination by miR-302. Biochem. Biophys. Res. Commun. 466, 180-185
45. Mihaylova, M. M., and Shaw, R. J. (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016-1023
46. Chun, M. J., Kim, S., Hwang, S. K., Kim, B. S., Kim, H. G., Choi, H. I., Kim, J. H., Goh, S. H., and Lee, C. H. (2016) AMP-activated protein kinase is involved in the activation of the Fanconi anemia/BRCA pathway in response to DNA interstrand crosslinks. Oncotarget 7, 53642-53653
47. Nijman, S. M., Huang, T. T., Dirac, A. M., Brummelkamp, T. R., Kerkhoven, R. M., D'Andrea, A. D., and Bernards, R. (2005) The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 17, 331-339
48. Kim, M., and Kim, J. M. (2016) The role of USP1 autocleavage in DNA interstrand crosslink repair. FEBS Lett. 590, 340-348
49. Raghunandan, M., Chaudhury, I., Kelich, S. L., Hanenberg, H., and Sobeck, A. (2015) FANCD2, FANCJ and BRCA2 cooperate to promote replication fork recovery independently of the Fanconi Anemia core complex. Cell Cycle 14, 342-353
50. Hayakawa, M. (2012) Role of K63-linked polyubiquitination in NF-B signalling: which ligase catalyzes and what molecule is targeted? J. Biochem. 151, 115-118
51. Lavorgna, A., and Harhaj, E. W. (2014) Regulation of HTLV-1 tax stability, cellular trafficking and NF-B activation by the ubiquitin-proteasome pathway. Viruses 6, 3925-3943
52. Zhang, H., Hu, H., Greeley, N., Jin, J., Matthews, A. J., Ohashi, E., Caetano, M. S., Li, H. S., Wu, X., Mandal, P. K., McMurray, J. S., Moghaddam, S. J., Sun, S. C., and Watowich, S. S. (2014) STAT3 restrains RANK-and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat. Commun. 5, 5798
53. Gallo, L. H., Meyer, A. N., Motamedchaboki, K., Nelson, K. N., Haas, M., and Donoghue, D. J. (2014) Novel Lys63-linked ubiquitination of IKK- induces STAT3 signaling. Cell Cycle 13, 3964-3976
54. Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreault, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008) cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689-700
55. Blakely, C. M., Pazarentzos, E., Olivas, V., Asthana, S., Yan, J. J., Tan, I., Hrustanovic, G., Chan, E., Lin, L., Neel, D. S., Newton, W., Bobb, K. L., Fouts, T. R., Meshulam, J., Gubens, M. A., et al. (2015) NF-B-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 11, 98-110
56. Dai, T., Zhang, D., Cai, M., Wang, C., Wu, Z., Ying, Z., Wu, J., Li, M., Xie, D., Li, J., and Song, L. (2015) Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma cell aggressiveness by activating the NF-B pathway. J. Pathol. 235, 490-501
57. Choi, Y. B., and Harhaj, E. W. (2014) HTLV-1 tax stabilizes MCL-1 via TRAF6-dependent K63-linked polyubiquitination to promote cell survival and transformation. PLoS Pathog. 10, e1004458
58. Li, Z., Younger, K., Gartenhaus, R., Joseph, A. M., Hu, F., Baer, M. R., Brown, P., and Davila, E. (2015) Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J. Clin. Invest. 125, 1081-1097
59. Sun, H., Li, X., Fan, L., Wu, G., Li, M., and Fang, J. (2014) TRAF6 is upregulated in colon cancer and promotes proliferation of colon cancer cells. Int. J. Biochem. Cell Biol. 53, 195-201
60. He, Z., Huang, C., Lin, G., and Ye, Y. (2016) siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells. Oncol. Rep. 35, 1933-1940
61. Shen, R. R., Zhou, A. Y., Kim, E., O'Connell, J. T., Hagerstrand, D., Beroukhim, R., and Hahn, W. C. (2015) TRAF2 is an NF-B-activating oncogene in epithelial cancers. Oncogene 34, 209-216
62. Kovalenko, A., Chable-Bessia, C., Cantarella, G., Israël, A., Wallach, D., and Courtois, G. (2003) The tumour suppressor CYLD negatively regulates NF-B signalling by deubiquitination. Nature 424, 801-805
63. Brummelkamp, T. R., Nijman, S. M., Dirac, A. M., and Bernards, R. (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-B. Nature 424, 797-801
64. Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., Ma, A., Koonin, E. V., and Dixit, V. M. (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-B signalling. Nature 430, 694-699
65. Hymowitz, S. G., and Wertz, I. E. (2010) A20: from ubiquitin editing to tumour suppression. Nat. Rev. Cancer 10, 332-341
66. Metzig, M., Nickles, D., Falschlehner, C., Lehmann-Koch, J., Straub, B. K., Roth, W., and Boutros, M. (2011) An RNAi screen identifies USP2 as a factor required for TNF-induced NF-B signaling. Int. J. Cancer 129, 607-618
67. Testa, J. R., and Tsichlis, P. N. (2005) AKT signaling in normal and malignant cells. Oncogene 24, 7391-7393
68. Altomare, D. A., and Testa, J. R. (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464
69. Chan, C. H., Jo, U., Kohrman, A., Rezaeian, A. H., Chou, P. C., Logothetis, C., and Lin, H. K. (2014) Posttranslational regulation of Akt in human cancer. Cell Biosci. 4, 59
70. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., Uhlik, M., Lin, A., Du, J., Qian, Y. W., Zeckner, D. J., et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448, 439-444
71. Yang, W. L., Wang, J., Chan, C. H., Lee, S. W., Campos, A. D., Lamothe, B., Hur, L., Grabiner, B. C., Lin, X., Darnay, B. G., and Lin, H. K. (2009) The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 325, 1134-1138
72. Chan, C. H., Li, C. F., Yang, W. L., Gao, Y., Lee, S. W., Feng, Z., Huang, H. Y., Tsai, K. K., Flores, L. G., Shao, Y., Hazle, J. D., Yu, D., Wei, W., Sarbassov, D., Hung, M. C., et al. (2012) The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149, 1098-1111
73. Wickliffe, K. E., Williamson, A., Meyer, H. J., Kelly, A., and Rape, M. (2011) K11-linked ubiquitin chains as novel regulators of cell division. Trends Cell Biol. 21, 656-663
74. Al-Hakim, A. K., Zagorska, A., Chapman, L., Deak, M., Peggie, M., and Alessi, D. R. (2008) Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33-linked polyubiquitin chains. Biochem. J. 411, 249-260
75. Morris, J. R., and Solomon, E. (2004) BRCA1: BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. Hum. Mol. Genet. 13, 807-817
76. McCarthy, E. E., Celebi, J. T., Baer, R., and Ludwig, T. (2003) Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol. Cell. Biol. 23, 5056-5063
77. Hashizume, R., Fukuda, M., Maeda, I., Nishikawa, H., Oyake, D., Yabuki, Y., Ogata, H., and Ohta, T. (2001) The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J. Biol. Chem. 276, 14537-14540
78. Elia, A. E., Boardman, A. P., Wang, D. C., Huttlin, E. L., Everley, R. A., Dephoure, N., Zhou, C., Koren, I., Gygi, S. P., and Elledge, S. J. (2015) Quantitative proteomic atlas of ubiquitination and acetylation in theDNA damage response. Mol. Cell 59, 867-881
79. Gatti, M., Pinato, S., Maiolica, A., Rocchio, F., Prato, M. G., Aebersold, R., and Penengo, L. (2015) RNF168 promotes noncanonical K27 ubiquitination to signal DNA damage. Cell Rep. 10, 226-238
80. Shen, M., Schmitt, S., Buac, D., and Dou, Q. P. (2013) Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin. Ther. Targets 17, 1091-1108
81. Farshi, P., Deshmukh, R. R., Nwankwo, J. O., Arkwright, R. T., Cvek, B., Liu, J., and Dou, Q. P. (2015) Deubiquitinases (DUBs) and DUB inhibitors: a patent review. Expert Opin. Ther. Pat 25, 1191-1208
82. Kushwaha, D., O'Leary, C., Cron, K. R., Deraska, P., Zhu, K., D'Andrea, A. D., and Kozono, D. (2015) USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-tohigh MCL1. Cancer Biol. Ther. 16, 392-401
83. Colland, F., Formstecher, E., Jacq, X., Reverdy, C., Planquette, C., Conrath, S., Trouplin, V., Bianchi, J., Aushev, V. N., Camonis, J., Calabrese, A., Borg-Capra, C., Sippl, W., Collura, V., Boissy, G., et al. (2009) Smallmolecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol. Cancer Ther. 8, 2286-2295
84. Pickart, C. M. (1997) Targeting of substrates to the 26S proteasome. FASEB J. 11, 1055-1066
85. Xu, P., Duong, D. M., Seyfried, N. T., Cheng, D., Xie, Y., Robert, J., Rush, J., Hochstrasser, M., Finley, D., and Peng, J. (2009) Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 137, 133-145
86. Lauwers, E., Jacob, C., and André, B. (2009) K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway. J. Cell Biol. 185, 493-502
87. Silva, G. M., Finley, D., and Vogel, C. (2015) K63 polyubiquitination is a new modulator of the oxidative stress response. Nat. Struct. Mol. Biol. 22, 116-123
88. Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., and Springer, W. (2010) PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 12, 119-131
89. Chastagner, P., Israël, A., and Brou, C. (2006) Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. EMBO Rep. 7, 1147-1153
90. Jura, N., Scotto-Lavino, E., Sobczyk, A., and Bar-Sagi, D. (2006) Differential modification of Ras proteins by ubiquitination. Mol. Cell 21, 679-687
91. Su, Y. T., Gao, C., Liu, Y., Guo, S., Wang, A., Wang, B., Erdjument-Bromage, H., Miyagi, M., Tempst, P., and Kao, H. Y. (2013) Monoubiquitination of filamin B regulates vascular endothelial growth factormediated trafficking of histone deacetylase 7. Mol. Cell. Biol. 33, 1546-1560